{"id":28149,"date":"2025-02-12T19:58:54","date_gmt":"2025-02-12T17:58:54","guid":{"rendered":"https:\/\/neuro.med.sumdu.edu.ua\/?p=28149"},"modified":"2025-05-02T09:50:03","modified_gmt":"2025-05-02T07:50:03","slug":"fda-approves-mirdametinib-for-the-treatment-of-neurofibromatosis-type1","status":"publish","type":"post","link":"https:\/\/neuro.med.sumdu.edu.ua\/en\/fda-approves-mirdametinib-for-the-treatment-of-neurofibromatosis-type1\/","title":{"rendered":"FDA approves mirdametinib for the treatment of neurofibromatosis type1"},"content":{"rendered":"<p><a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic\" target=\"_blank\" rel=\"noopener\">The FDA has approved mirdametinib<\/a>, the first oral drug for treating plexiform neurofibromas in patients with neurofibromatosis type 1 (NF1). The drug is indicated for adults and children aged 2 years and older who have symptomatic or inoperable tumours. This decision opens up new opportunities to improve the quality of life for patients with this complex disease.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA has approved mirdametinib, the first oral drug for treating plexiform neurofibromas in patients with neurofibromatosis type 1 (NF1). The drug is indicated for adults and children aged 2 years and older who have symptomatic or inoperable tumours. This decision opens up new opportunities to improve the quality of life for patients with this [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":28353,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[655],"tags":[],"class_list":["post-28149","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/posts\/28149","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/comments?post=28149"}],"version-history":[{"count":2,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/posts\/28149\/revisions"}],"predecessor-version":[{"id":28151,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/posts\/28149\/revisions\/28151"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/media\/28353"}],"wp:attachment":[{"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/media?parent=28149"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/categories?post=28149"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neuro.med.sumdu.edu.ua\/en\/wp-json\/wp\/v2\/tags?post=28149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}